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ABSTRACT
Motivation: Analysis of high-throughput proteomic/genomic data, in
particular, surface-enhanced laser desorption/ionization time-of-flight
mass spectrometry (SELDI-TOF MS) data and microarray data, has
led to a multitude of techniques aimed at identifying potential biomarkers. For SELDI-TOF MS data, most of these techniques rely on
arbitrary, user-defined rules for identifying peaks and do not control
for global error, potentially leading to false positives.
Results: We have devised a simultaneous confidence bands method
capable of detecting potential biomarkers, while controlling for overall Type I error, in high-dimensional genomic/proteomic datasets that
discriminate two treatment groups using a permutation scheme. For
example, for the SELDI-TOF MS data, we treat the entire spectrum
as a stochastic process and construct  confidence bands
for the mean differences between groups. Furthermore, peaks were
identified based on the maximal differences between the groups as
determined by the confidence bands. The analysis method herein
described gives both qualitative (significance in terms of p-value) and
quantitative data (magnitude of difference). The Clinical Proteomics
Programs Databank’s ovarian cancer dataset and data from in-house
samples containing known spiked-in proteins were analyzed. We
were able to identify potential biomarkers similar to those described
in previous analysis of the ovarian cancer data, however, while these
markers are highly significant between cancer and normal groups, our
analysis indicated the absolute difference between the two groups
was minimal. In addition, we found additional markers than those
previously described with greater differences in average intensities.
The proposed confidence bands method successfully detected the
spiked-in peaks, as well as, secondary peaks generated by adducts
and double-charged species. We also illustrate our method utilizing
paired gene expression data from a prostate cancer microarray experiment by constructing confidence bands for the fold changes between
cancer and normal samples.
Availability: The R and C codes are available from the authors.
Contact: park@jimmy.harvard.edu





1 INTRODUCTION
Microarray and mass spectrometry technologies require effective
statistical/computational methods that find important biomarkers,
defined as features (genes/proteins), differentially expressed between two groups of samples within thousands of features. An
inherent problem in analyzing such high-dimensional data is the
detection of false positives if one uses separate statistical tests for
each feature using traditional p-value cutoffs of 0.01 or 0.05, due
to a large number of features which are potentially correlated with
each other by unknown fashion. This multiplicity problem has been
widely studied in the statistical literature (Benjamini & Hochberg
1995, Lehmann. 1986, Hochberg & Tahmhane 1987, Westfall &
Young. 1993) and recent papers analyzing microarray experiments
(Dudoit et al. 2003, Efron et al. 2002, Golub et al. 1999, Pollard &
van der Laan. 2003, Tusher et al. 2001).
However, most of the ideas introduced for biomarker detection
in high-dimensional data, so far, were originated from hypothesis
testing, rather than interval estimates for the difference between two
groups. While such two-sample tests only detect a qualitative significance of difference (p-value) that measures how likely markers are
to distinguish between two sample groups, interval estimates are
much more informative by giving quantitative importance of the
markers (multitude of contrast between groups) on top of qualitative importance. For example, if the 95% confidence interval for
the mean difference in expression between two groups for gene A
is (20, 40), then gene A is a statistically significant difference between groups with a p-value less than 0.05 and the magnitude of
difference in expression can range from 20 to 40 with 95% confidence. However if that for gene B is (-20, 10) indicating the mean
expression difference for gene B between groups can be 0, then the

p-value for testing gene B is greater than 0.05. Likewise, 

interval estimates corresponds to the testing with a level of . Usefulness of such interval estimation is well acknowledged in the
statistical literature, however, simultaneous interval estimation for
high-dimensional data has not been widely considered due to complications arising from the unknown dependence between structures
within a large number of features.
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We propose a new and simple algorithm based on permuta 
tion method to construct 
simultaneous and exact confidence bands for any contrast assessment between groups with
high-dimensional data sets. The proposed method allows for visualization of the possible range of difference in protein/gene abundance
between groups with statistical significance while simultaneously
controlling for overall type I error. We consider comparisons not
only between two independent samples, but also dependent paired
samples. One of the most intuitive contrast measurements would
be mean difference between two groups and it is usually tested by
 -statistics. Our method can be flexibly generalized to construct confidence bands for general two- or one-sample test statistics, such as
Wilcoxon test statistics.
The confidence bands method can be applied to different data sets
including microarray, CGH/SNP experiments, or proteomics data.
In particular, we found this method to be very useful for exploring
proteome-wide biomarkers using SELDI-TOF MS technology.
Conventional methods for analyzing SELDI-TOF MS data first
detect the peaks in a spectrum generated for each sample after calibration and then align these peaks across the samples. Next, peaks
related to a mass-to-charge ratio (m/z) that discriminate groups
based on testing of peak intensities are determined. However, the
peak detecting methods are controversial because they are ad-hoc
and the results can vary due to user-defined parameters such as
signal-to-noise ratio. To tackle this problem, researchers have used
“fingerprints” (Fung et al. 2001 and Vlahou et al. 2001), however, this method does not allow for individual peak labeling and
subsequent protein identification. Morris et al. 2005 introduced
a new peak detection method based on the mean spectrum and
demonstrated that the usage of the spectrum average leads to greater
sensitivity and specificity while eliminating the difficult and intrinsically error-laden step of matching detected peaks on individual
spectra.
In the confidence bands method, we define a new concept for
peaks (biomarkers) based on the proposed confidence bands. We
use all the intensity data and treat them as a stochastic process along
the spectrum without a peak calling procedure. After constructing
 

confidence bands for the mean difference between groups
along the entire spectrum, we automatically search for peaks, with
mass accuracy adjustment, that have the maximal differences between groups as determined by the confidence bands. In this way,
we can obtain the statistically meaningful peaks that discriminate
two groups with qualitative and quantitative significance.
First we used well-known SELDI-TOF MS data sets from the
latest experiment for ovarian cancer in the Clinical Proteomics Programs Databank (http://clinicalproteomics.steem.com). This dataset
has been discussed by several papers (Petricoin et al. 2002, Sorace
& Zhan 2003, Baggerl et al. 2004, Diamandis 2004), and has been
controversial. We re-analyzed the data and compared our results
with the results from these papers. We also performed a spike-in
experiment with samples from 91 prostate cancer patients to assess
the accuracy of our methods.
For demonstrating our method for matching paired samples and
other high-dimensional data, we also constructed confidence bands
for the fold change between cancer and normal samples for a prostate cancer microarray experiment with 46 matching pairs that was
used in Singh et al. 2002.

2 STATISTICAL METHODS
Suppose that we are interested in making inferences about the difference
based on a large set of measurements from
between two groups, and

each study subject. That is, the response random vector for is
and is
for
where is the index



set. Furthermore, we assume that there exists an unknown constant vector
such that
 
 
 having the same distribution as
that of
 Let

be
independent copies of
be independent copies of
 and


We are interested in constructing a     simultaneous confidence band
for
That is,
  where
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since we do not know the dependence structure among the components of
  nor of   5 the cutoff points L D and M D are difficult, if not
impossible, to obtain analytically even for the case with large sample sizes
- and 4R$
Here, we utilize a simple permutation idea to obtain these cutoff point L D
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where the probability is generated from the random samples  /

*)+)+),4R and  %  &R(+)*)+)B-.$ If the left hand side of (2.4) is less
than   Rl5>  then L is greater than L D $ To obtain a good approximation
to L D  in practice, first, we let LopC DFE*G and if (2.4) is satisfied, we then
increase L by a small value, say, 0.01 and check (2.4) again. We continue
this process until (2.4) is violated.
To obtain@ the upper bound M D  we let M be a positive number and
rq N X OMgY $ We let  /   21 +)*)+),4W be random sample for a population consists of Z5/  s q  21t
+)*)+),4 and

[F%  &" (*)+)*),-.$ Moreover,
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Otherwise, Mz^M D $ Again, one may start with Mo|C DFE*G  check (2.5) and
continue this process by adding a small value to M if necessary.
These confidence bands (2.3) can be graphically displayed with two curves along  indicating the possible range of the difference between
mean expression of two groups with    confidence. Therefore, if (2.3)
for does not include 0, such is significantly differentially expressed with
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a level of  (in other words, p-value  ). Here, a collection of such significant values is denoted by the significant region .
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APPLICATION TO MASS SPECTROMETRY
DATA ANALYSIS
3.1 Finding the Potential Biomarkers (peaks) for
SELDI-TOF MS data

3.2 Application to Petricoin’s ovarian SELDI-TOF MS
dataset
We analyzed the latest SELDI-TOF MS data from the ovarian cancer study available in the Clinical Proteomics Programs Databank
with our method. This set of data consists of serum profiles of 162
subjects with ovarian cancer and 91 non-cancer control subjects. For
each subject, a set of data consisting of intensities at 15,154 distinct
m/z values ranging from 0.0000786 to 19,995.513 was available
for analysis. This dataset was constructed using Ciphergen WCX2
ProteinChip Arrays. Preparation of chips for sample analysis was
performed robotically and the raw data, without baseline subtraction, was posted for download. We used the normalization method
outlined in the Clinical Proteomics Databank by scaling the intensities value between 0 and 1. Additional details of experimental
data collection can be found at the Clinical Proteomics Programs
Databank. We analyzed the ovarian cancer dataset with all 11,003
m/z data points within the m/z range of = [1,500 m/z, 20,000
m/z] for 91 normal and 162 tumor samples. The intensity measures
within the rage below 1500 m/z were discarded due to the effects
of matrix. Table 1 shows the cut-off points, D and D , for the confidence bands, with levels of, 0.005, 0.01, and 0.05 with the total
permutation number of
= 10,000.









Table 1. The cut-off values of 99.9%, 99.5%, 99% and 95% confidence
bands for Petricoin’s ovarian cancer dataset

   

LD MD

CB ( , )
Bonferroni

99.9%

99.5%

99%

95%

(4.10, -3.85)
5.40

(3.50, -3.50)
5.11

(3.30, -3.25)
4.97

(2.95, -2.90)
4.65

3

The mass-axis of the SELDI-TOF MS output shifts from experiment
to experiment by approximately
0.2-0.5% of the m/z values.
Based on the confidence bands, we searched for peaks that may
be potential biomarkers with, say
0.5%, mass accuracy. These
peaks best discriminated two groups both qualitatively and quantitatively among the significant regions found in the test. First, we

defined the minimum-potential-change (MPC) at m/z as the mini
mal absolute change between the mean intensities at m/z of two

groups with confidence. Therefore if the two confidence bounds at
m/z include zero, then MPC should be 0 and if not, then MPC would

be either the lower bound for positive mean difference at m/z or the

absolute value of the upper bounds for negative mean difference at

m/z. Let’s say that the m/z value with the largest MPC is . We then
   
  
 
updated by removing all satisfying 
.

This process was repeated until there existed unique per each
window in the significant region . Furthermore, we excluded the
m/z values that were not apexes among remaining by examining
the slopes of the curves of observed difference of mean intensities of
two groups. We concluded that the final was the list of important
biomarkers.


 



    


The cut-off values were relatively smaller than the Bonferroni’s
adjusted cut-off values which are the cut-off values under the conservative assumption that intensities for individual m/z points are
independent. Figure 1 shows the 95% confidence bands for the differences in mean intensity between cancer and normal patients. We
obtained the significant region (the shaded regions in Figure 1) by

excluding values including 0 within the 95% confidence bands for
further analysis.
We next followed the procedure of the section 3.1 with a mass
precision of 0.5% and found 48 biomarkers in the region of as
significant peaks with 95% confidence. Figure 2 illustrates (a) adjusted p-value curve by maxT method (Westfall & Young, 1993);
A higher p-value curve indicates greater significance of difference
between the two groups at that m/z value, and (b) 95%, 99.5%
confidence bands in the region of [6700m/z, 8100m/z]. The outer
dotted lines are 99.5% and the inner dashed lines are 95% confidence bands since larger ranges for the difference are produced for
higher confidence level.
It is important to note that the confidence bands give more information than global p-value curve. Whereas the conventional p-value
curve only tests if two groups are different to each other with level of

, the confidence bands actually show the magnitude of differences
 
with the corresponding confidence of
. Moreover, p-value curves alone do not give information about the precise m/z position for
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P BB

P

CC

P

CB

−log10(p−value)

2

MPC

0.10

−0.1

p−value=0.005

p−value=0.05

0

0.00

−0.3

1

0.05

−0.2

Mean differences

0.15

3

0.0

B

2761
5000

10000

15000

3498

3991

6632

7947

m/z

20000

Mass/Charge

Fig. 1. 95% proteome-wide confidence bands for Petricoin’s ovarian MS
dataset

Fig. 3. Minimum potential changes (MPC) and p-values for detected peaks
by CB (C), Petricoin’s (P), and Baggerly’s (B) methods

4

(a) Global p−value curve, 6700−8100 m/z

2

0.005 level

0.05 level

Table 2. Top five significant markers at the level of 0.05 detected by
Baggerly’s, Petricoin’s, and the CB methods

0

1

−log(p−value)

3

detected by our method with significant peaks reported in the Clinical Proteomics Databank and those from Baggerly et al. We report
their observed mean difference (cancer-normal) and 95% confidence
bands in Table 2.

6800

7000

7200

7400

7600

7800

0.1
0.0
−0.1
−0.2

Petricoin’s method

Baggerly’s method

m/z

95% CB

m/z

95% CB

m/z

95% CB

3900
7947
7990
8351
4185

(-0.37, -0.21)
(-0.28, -0.15)
(-0.27, -0.15)
(-0.24, -0.14)
(-0.15, -0.09)

2761
19643
6632
14052
3498

(-0.003, 0.005)
(0.001, -0.003)
(-0.009, 0.002)
(-0.002, 0.004)
(-0.001, 0.010)

1531
3010
3200
8033

(-0.006, 0.017)
(-0.001, 0.007)
(0.001. 0.009)
(-0.17, -0.10)

−0.3

Mean differences

CB method

8000

m/z
(b) 95%, 99.5% Confidence bands, 6700−8100 m/z

6800

7000

7200

7400

7600

7800

8000

Fig. 2. Zoom-in figure within the region of [6,700 m/z, 8,100 m/z] for (a)
global p-value curve and (b) 95%, 99.5% confidence bands for Petricoin’s
ovarian MS dataset

potential biomarkers. For example, the peak at 6800 m/z was found
to be as significant in the p-value curve as the region 7700 - 8000 m/z
(p-value 0.0001). However, the confidence bands indicate that the
region 7700-8000 m/z contains four individual peaks, each with a
greater magnitude of difference that the single peak at 6800 m/z. In
this way, we were able to find potential biomarkers based on actual
contrast between two groups, not arbitrary ad-hoc ways of defining peaks. We sorted 48 detected markers based on their minimum
potential changes, (The data can be found in the supplementary
documentation at http://research2.dfci.harvard.edu/dfci/MS spikein data/), and we compared the top five significant biomarkers



Figure 3 shows the MPC curves (left y-axis and black solid
curves) and p-value curves (right y-axis and grey curves) for m/z
values which were determined to be significant in these two papers.
Although there was no direct match between peaks identified by
Petricoin et al. and the CB method, Petricoin’s peaks at 2761, 3498
and 6632 were within 1% m/z of CB method detected peaks that
have significant p-values but relatively small MPC (Figure 4). This
may be due to incorrect peak-calling. Only two m/z at 3200 and
8033 detected by Baggerly et al. 2004 were found to be significant
in our methods, however, the magnitude of difference between the
groups at these two m/z values was again low when compared to the
top markers identified using the CB method.

3.3

Application to the Spike-in Study

Plasma samples from 91 prostate cancer patients were divided
into 7 age matched groups consisting of thirteen samples. The
groups were labeled A-G. Groups B-F were spiked with five proteins at 1X, 2X, 5X, and 10X concentrations in a “Latin Square”

5
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formation (Table 3). The minimal concentration of each of the
spiked proteins allowing for a detectable peak in plasma was previously determined (data not shown). The minimal concentration
for each protein was labeled as 1X and was found to be 1 fmol/ L
for cytochrome c (from bovine heart, Sigma, St. Louis, MO), 10
fmol/ L for ubiquitin (from bovine red blood cells, Sigma), lysozyme (from chicken egg white, Sigma), and myoglobin (from horse
heart, Sigma), and 100 fmol/ L for trypsinogen (from bovine pancreas, Sigma). The volume of spiked-in proteins was fixed at 10% of
the plasma volume. Group A was not spiked with protein, however,
an equal volume of diluent was added. Group G contained all five
proteins at maximal (10X) concentrations.
Table 3. “Latin Square” design and protein concentrations

Groups

Cytochrome c

Ubiquitin

Lysozyme

Myoglobin

Trypsinogen

A
B
C
D
E
F
G

0X
0X
1X
2X
5X
10X
10X

0X
1X
2X
5X
10X
0X
10X

0X
2X
5X
10X
0X
1X
10X

0X
5X
10X
0X
1X
2X
10X

0X
10X
0X
1X
2X
5X
10X

Proteins 1X= Ubiquitin (1 fmol/ L), Cytochrome/Lysozyme/Myoglobin (10 fmol/ L), Trypsinogen(100 fmol/ L)






Following the addition of proteins, 20 L of each plasma sample was diluted with 30 L 9 M urea and incubated at 4 C for 30
minutes in order to denature proteins. The samples were further diluted with 150 L 1 M urea and subsequently stored at -80 C until
analyzed by SELDI-TOF MS.
Using a Biomek 2000 (Beckman Coulter, Fullerton, CA), CM10
ProteinChip Arrays (Ciphergen Biosystems, Freemont, CA) were
washed two times with 150 L CM Low Stringency buffer (Ciphergen) with shaking for 5 minutes at room temperature. Following the
wash step, 90 L of buffer was aliquoted onto each spot of the array
and 10 L of sample was then added. The arrays were shaken for 30
minutes at room temperature to allow for protein binding to the surface chemistry. Subsequently, the diluted samples were removed and
the arrays were washed three times with 150 L buffer, with shaking
for 5 minutes per wash at room temperature, and rinsed twice with
200 L water. The arrays were air dried and 1 L of sinapinic acid
(Ciphergen) was added twice to the arrays. The samples were analyzed on a PBSIIc SELDI-TOF mass spectrometer (Ciphergen) per
manufacturer’s instructions at a laser setting of 190, detector setting
of 7, and a digitizer rate of 1000.
The data was baseline subtracted and normalized by total-ion
current using Ciphergen Express (Ciphergen). From the five purity
spectra that contain a single spiked-in protein (http://research2.dfci.
harvard.edu/dfci/MS spike-in data/), we found that SELDI-TOF
MS experiments often produce secondary peaks, in addition to
expected peaks, generated by multiple-charged species or matrix
adducts for each of the five proteins. Moreover, we observed several
peaks generated from contaminants within the pure spiked-in proteins. We also observed the intensities for group G, which contained
all five proteins in maximal concentrations, were generally lower


than those for other groups with maximal concentration most likely
due to ion suppression. (The mean intensity curves of groups A-G in
the m/z regions of each spiked-in protein with 0.5% precisions can
be found in the supplementary documentation.) To assess the accuracy of detecting known proteins using the confidence band method,
we compared all 21 possible pair-wise comparisons for groups A to
G without knowledge of the five spiked-in proteins. Only the researcher conducting the SEDI-TOF MS knew the protein concentrations
in each group and he did not take part in the analysis. We found 133
peaks as significant with 95% confidence. Table 4 reports the top
ten detected peaks sorted primarily by the number of comparisons
in which the peaks were detected as significant and secondarily by
the largest MPC among the results from all comparisons between
groups.



Table 4. Top 10 detected peaks from the CB methods with 95% confidence
for the spiked-in experiment

m/z

95% CB

Comparison groups

Identity

8473
12234*
16952*
14301*
15203*
23979*
7146*
14521*
15380
14691

(9.17, 12.46)
(6.02, 8.73)
(39, 4, 9.17)
(36.34, 45.92)
(-11.69, -9.17)
(8.48, 12.61)
(5.97, 8.39)
(4.72, 7.03)
(2.30, 3.85)
(1.11, 1.74)

ca
ga
ca
da
cb
ba
da
da
fc
ga

Myoglobin+2H+
Cytochrome c
Myoglobin
Lysozyme
Trypsinogen Impurity
Trypsinogen
Lysozyme+2H+
Lysozyme+SPA
Trypsinogen Impurity
Lysozyme+2SPA

* also found in top 10 by Ciphergen Express analysis



Ciphergen’s biomarker detection algorithm, Ciphergen Express,
found 124 significant markers with a level of 0.05 [data are not
shown]. Their top 10 detected peaks also contained four of the five
spiked-in proteins. Curiously, ubiquitin was not found to be one of
the top ten most significant peaks. This may have been due to the
decrease in intensity observed at higher concentrations for ubiquitin
(supplementary figure). The resultant lower MPC resulted in ubiquitin being ranked as the 12th most significant peak, as determined by
our analysis.
Baggerl et al. (2004) discussed the problems behind calibration, background subtraction, and normalization of data. In order to
address these potential problems, we further analyzed our spikedin data set to examine the effects of background subtraction and
normalization. The total-ion current method of normalization assumes that the total amount of proteins in each sample may vary
due to sample handling or instrument sensitivity. In general, with
the exception of known disease states, the protein concentration of
blood samples falls within a narrow range, but since the amount
of proteins in the spike-in study may vary across the samples in
different groups overall intensities may have been over-normalized
with the total ion current method. We analyzed the raw data
without background subtraction and normalization, and obtained
137 significant markers which contained 94 out of 133 markers
detected from the analysis with the background subtraction and
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Simultaneous and exact interval estimates for the contrast of two groups based on an extremely high dimensional response variable
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Fig. 4. 99% Confidence bands of the fold-change between paired tumornormal samples of Singh et al.’s prostate cancer microarray experiment

normalization with 95% confidence bands (The detail of analysis can be found at http://research2.dfci.harvard.edu/dfci/MS spikein data). Spiked-in proteins were detected as with spectrum processing. The raw data from our spike-in study is posted at
http://research2.dfci.harvard.edu/dfci/MS spike-in data/.

4

APPLICATION TO MICROARRAY DATA (PAIRED
SAMPLES)

We applied our confidence band method to a previously published
prostate cancer microarray experiment (Affymetrix H95Av2 containing 12,600 probesets) (Singh et al. 2002). Of the 52 prostate
tumor and 50 normal samples, 46 were matching pairs. The paper
ignored this dependency within the same patients and obtained 456
differently expressed genes at the level of 0.001 using the signal-tonoise method of Golub et al. 1999. We re-analyzed this data with our
confidence bands method with the paired data and found 71 genes
to be significantly different between cancerous and normal tissue at
the level of 0.001. Our smaller number of significant genes indicates that previous analysis likely yielded many false-positives due
to incorrect multiple-comparisons and neglect of the dependency
of matching samples. Figure 4 shows 99% confidence bands of 71
significant genes sorted by their minimum-potential-change.

5

DISCUSSION

In this article, the approach we took for finding biomarkers in
high-dimensional genomic/proteomic data is quite different from
methods previously reported. Rather than determining qualitatively
significant markers (with small p-value), we attempt to measure
both qualitative and quantitative importance of markers by exploiting simultaneous confidence bands that reflect the true random

fluctuation in the difference between groups of samples. Our algorithm cleverly bypasses the curse of dimension for estimating the
high-dimensional parameters to obtain the interval estimates of the
difference between groups, by reducing the problem into estimating

D  in (2.3). The proposed method is flexible
two parameters,  D
and can be extended to general two/one-sample test statistics. For
example, if one wants to use a rank-based test, one can construct
confidence bands for the median difference between groups. Our
method also allows for the analysis of paired samples.
Although our method is applicable to any high-dimensional data,
we extensively studied SELDI-TOF MS data as our major application. While SELDI-TOF MS technology has been acclaimed as one
of the most powerful new frontiers among disease diagnosis technologies utilizing blood-borne proteins, inconsistent results from
previous publications indicated the necessity of new, refined approaches to derive optimal biomarkers that can be both interpreted and
accepted by the scientific community. Petricoin et al. (2002)’s claim
that they can predict the presence of ovarian cancer using SELDITOF MS data with 100% accuracy has brought great attention, as
well as, controversy. Zhu et al. (2003) also studied the early dataset
used by Petricoin et al. (2002) and published a non-overlapping set
of markers. Baggerly et al. (2004) also pointed out that the markers
detected by Petricoin et al. (2002) were not significant in terms of
 -statistics, leading to suspicion of their importance as discriminating biomarkers between cancer and normal samples. Solace & Zhan
(2003) found markers using the latest dataset from Clinical Proteomics (the same set used for our results), however, the majority of
their markers were less than 500 m/z and were likely to be artifacts or experimental bias as these are within the noise signal of the
energy absorbing matrix. Our confidence bands method provides a
new, alternative way to detect the potential biomarkers throughout
the whole m/z region. Our method provides a powerful visualization tool for detecting potential markers with both qualitative and
quantitative importance of markers without arbitrary peak-calling.
Furthermore, our method detects a precise position for each peak
that discriminates between two groups based on MPC with massaccuracy adjustment. According to Diamandis (2004), SELDI-TOF
technology is not capable of detecting any serum component at concentrations of less than 1 g/mL and statistically significant markers
with such small differences are often detected due to artifacts related to the nature of the clinical samples used or the MS instruments.
Therefore, it is quite informative to sort the list of potential biomarkers by corresponding MPCs indicating the relative magnitude
of protein abundance compared to control samples.
While the spike-in experiment did not generate a clean data set
that contained only the spiked-in proteins as significant peaks in the
spectrum, it was a valuable experiment to understand the nature
of SELDI-TOF MS and to evaluate the performance of our CB
method. The five proteins were initially chosen because unfractionated human plasma does not have peaks at the corresponding
molecular weights on the Ciphergen cationic chip surface and all
have isoelectric points at least 2 units above 4, the pH at which the
low stringency wash was performed. While only the five spikedin proteins were expected, the CB method detected 133 significant
peaks. Most of the peaks were artifacts typical of the SELDI-TOF
MS method, such as, EAM adducts, multiple charged species, and
ion suppression (see Table 4 for examples of the former two). The
albumin peak at approximately 66,500 daltons was found to be
significantly different between the groups (data not shown). This

 

7

Hosted by The Berkeley Electronic Press

Yuhyun Park et al

was due to ion suppression caused by an increase in cytochrome
c levels as evidenced by groups E-G having the lowest levels of
albumin and the highest levels of cytochrome c. Furthermore, some
of the additional, unexpected peaks were found to be contaminants
in the stocks of “pure” proteins. The stock of trypsinogen contained several peaks that could not be attributed to any of the typical
artifacts and SDS-PAGE demonstrated that these excess peaks were
in fact contaminating proteins. One of these impurities, at an m/z
of 15,203, was found to be significantly different, in fact, it was
one of the top ten peaks detected by both the CB and Ciphergen
analysis methods. A second peak at 15,380 m/z, also identified as
a top ten discriminating marker, may have been the EAM adduct
of the 15,203 m/z peak as it was within 0.2% of the expected
mass-to-charge ratio. Curiously, these peaks did not have a maximal MPC in comparison to group A as expected, but rather with
group C. Group C was the experimental group that did not contain trypsinogen, but did contain all of the other proteins. The
contaminants were detected at the highest levels in groups B and
F containing 10X and 5X trypsinogen, respectively. It should be
noted that two of the proteins did not exhibit a linear relationship
between intensity and concentration when placed into plasma (Supplementary figure f). Ubiquitin demonstrated a biphasic response
with increasing intensity to a maximal at 2X concentration and then
a reduction in intensity at higher concentrations. Trypsinogen showed no difference in intensity between 1-5X concentration with a
marked increase in intensity at 10X. Considering the fact that different spiked-in proteins yielded different levels of increment in
intensities, it would be worth-while to consider constructing confidence bands for log-fold changes by talking the log-transformation
of the spectra intensities. Our method was successful in detecting
the spiked-in proteins robustly, regardless of background subtraction and normalization. The described experiment also demonstrates
some of the potential hazards of conducting spike-in studies.
Simultaneous confidence band method is a well-established inference scheme in statistical literatures, however, it has not been
exploited in bioinformatics thus far. This type of interval estimates for contrast between groups can be very attractive for genomic/proteomic datasets since this method allows investigators to
visualize the potential differences of mean intensities between
groups while guarding against false-positives due to multiple comparisons. It also yields meaningful biologically peaks rather than
arbitrary, user-defined peaks for SELDI-TOF MS data.
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